tert-Butyl (6-formylpyridin-2-yl)carbamate, 95.0%, 1g

3-VINYLOXETAN-3-OL, 95.0%, 1g

Azoture de sodium, min 98 %, pour synthèse, 100 g, emballage plastique.

2-(7-Aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate, 98.0%, 10g

7-METHOXY-4(3H)-QUINAZOLINONE, 95.0%, 5g

2-Fluoro-N-(2-nitrophenyl)aniline, 95.0%, 5g

1-(3,4-Dimethoxy-benzyl)-5-oxo-pyrrolidine-3-carboxylic acid methyl ester, 95.0%, 1g

tert-Butyl 1-bromo-3,6,9,12,15,18-hexaoxahenicosan-21-oate, 95%, 250mg

(1S)-3,3'-Bis[2,4,6-tris(1-methylethyl)phenyl][1,1'-binaphthalene]-2,2'-diol, ��97.0%, 500mg

2-Isopropyl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane, 97.00%, 1g

1-(4-Methyl-pyridin-2-yl)-1H-pyrrole-2-carbaldehyde, 95.0%, 10g

(2E)-1-(4-methylphenyl)-3-[4-(propan-2-yl)phenyl]prop-2-en-1-one, 95.0%, 10g

7-(tert-Butoxycarbonyl)-5,6,7,8-tetrahydro-1,7-naphthyridine-3-carboxylic acid, 97%, 1g